Andrew Cottone, Ph.D.
Andrew Cottone, Ph.D. is the President of Adesis, a position he has held since 2016, when the Company became a wholly-owned subsidiary of Universal Display Corporation (Nasdaq: OLED). Andrew joined CB Research and Development (the predecessor of Adesis) in 2001 and co-founded Adesis in 2005. Trained as an organometallic and process chemist, Andrew’s breadth and depth of experience encompasses 5 years of industrial experience as a process chemist, ten years as a technical manager, twelve years as an entrepreneur/business founder, and fifteen years as a business executive. As a research manager, he has been responsible for as many as 40 chemists with expertise in physical chemistry, organometallic chemistry, analytical chemistry, and organic chemistry. As a business executive/owner, Andrew has charted and steered the vision and growth of Adesis over the past 15 years and is responsible for greater than 100 Adesis employees across multiple sites.
Andrew graduated from La Salle University (Philadelphia, PA) in 1996 with a dual-bachelor’s degree in chemistry and biochemistry and received his Ph.D. in organometallic chemistry in 2000 from the University of Florida under the joint mentorship of Professors Dr. Russell S. Drago and Michael J. Scott. His doctoral research experience of substrate-metal complex interactions has provided insights into new reactions for preparative scale functionalization of azoles. Andrew completed a post-doctoral position under Dr. Charles Riordan at the University of Delaware, and then embarked on a dual science and business career under the mentorship of Drs. Charles Beard and Ving J. Lee. His personal passions include family, process chemistry, and all things Philadelphia.
Vice President of Business Development
Being in leadership roles within the pharmaceutical industry for several years, Mr. Foytlin has a depth of experience driving commercial innovation, building and leading high-performing teams, and managing and implementing change. He has a broad background in commercial roles, finance and analytics, tendering and contracting, and account management. For over 20 years, Mr. Foytlin has worked in North America, Europe, and Asia and has held leadership, business development, sales, and marketing roles at Sumitomo, Asahi Glass Corporation, Girindus/Solvay, Dishman, and Sanofi-Aventis. Rounding out his business development experience, Mr. Foytlin has conducted financial valuation and mergers and acquisition modeling to build, lead, and present business cases for internal and external stakeholders in the areas of M&A and strategic partnerships.
Mr. Foytlin received his BA from Villanova University and an MBA from Fordham University. He also holds alumni status from the Columbia University School of Business.
Mr. Gilligan has over 20 years of financial management and operations management experience for privately-held and publicly-traded companies, serving in the capacities of Controller, CFO, & COO. In addition, Mr. Gilligan spent five years working at public accounting firms and has served on various Board of Directors. Mr. Gilligan holds a Bachelor of Science in Business Administration from Kutztown University of Pennsylvania.
Manager, Facility & Procurement
Mr. Church began his career in chemical sales and hazardous waste management, and has 18 years of Management experience. He joined CB Research & Development in 2000 and Adesis in 2005. Mr. Church holds an Associates of Science in Business Management from Goldey-Beacom College.
Ving J. Lee, Ph.D.
Chief Scientific Officer
Dr. Lee received his BA and M.S.-Ph.D. from the Ohio State University and University of Illinois at Champaign-Urbana, respectively, and held postdoctoral fellowships at U. Illinois and Harvard University (NIH). He has held leadership and technical positions at Lederle Laboratories (Cyanamid), Microcide Pharmaceuticals, Iconix Pharmaceuticals (Iconix Biosciences), Anacor Pharmaceuticals, Limerick Biopharma, and CB Research and Development.
For most of his career, Dr. Lee has conducted multi-disciplinary programs with significant research components in discovery and preclinical technology. From 2002 to 2004, Dr. Lee was Chief Scientific Officer and Vice President, Discovery Research at Anacor Pharmaceuticals, Inc. where he directed research on boron-based therapeutics with support from a $22.6M Defense Advance Research Projects Agency (DARPA) contract. At Microcide, Dr. Lee held various positions including Vice President, Chemistry and Pre-clinical Research, Research Operations and Technology Assessment, and Senior Research Advisor responsible for research in beta-lactams for problematic gram-positive pathogens, uridyl-peptide antibiotics for problematic gram-negative pathogens, and inhibitors of bacterial efflux pumps. While at Lederle, he was responsible for the discovery of new anti-infectives, including the glycylcyclines, carbapenems, enhanced third-generation cephalosporins, beta-lactamase inhibitors, and new oncology agents.
Thematically, Dr. Lee’s research has encompassed i) eukaryotic systems biology considerations in the design of new molecular entities against prokaryotes based on natural product scaffolds, ii) understanding the function of eukaryotic transporters in drug deposition and metabolism, and iii) prokaryotic resistance factors. On the chemistry side, he has exploited i) the subtle reactivity found with certain natural products and ii) novel heterocycles with newer synthetic methods to create new molecular entities. This is exemplified by the incorporation of biological and metabolic considerations in the design of building blocks in the Adesis Catalog of Heterocyclic Intermediates initiative.
Dr. Lee is also advisor for several private and public biotech companies, venture capital firms, and co-founder of another biotech firm. He also serves on several National Institutes of Health study sections.
John Chiarello, Ph.D.
Vice President of Chemistry
Dr. Chiarello received his BS and Ph.D. from the College of New Jersey and the University of Pennsylvania, respectively. He has held positions of technical and managerial responsibilities in animal husbandry, drug discovery, and selective agricultural growth regulants, as well as insect control agents at American Cyanamid, Fort Dodge Animal Health (Wyeth), and FMC. Dr. Chiarello joined Adesis in 2006 and has held positions of increasing responsibilities including multi-project leadership in process and discovery projects.
Director of Operations
Ms. Baylis-Powell has over 25 years of fiscal and contract management experience in the private and municipal sectors. She joined CB Research and Development, Inc. in 2001 and Adesis, Inc. in 2005. Ms. Baylis-Powell is responsible for the areas of contract management, finance, and operations. Her first career position was with a chemical manufacturer as a quality control chemist, supervising a 24-hour laboratory. Ms. Baylis-Powell holds a Bachelors of Science degree from the University of Maryland.
Senior Leadership Team
In addition to breadth of technical experience, a strength of Adesis’ senior management is their corporate tenure. Operationally, we grow our management team organically with personnel that fully understand the organization’s entrepreneurial, technical, and project management needs. The collective Adesis experience for the personnel shown is 60+ years.
Members (left to right) Douglas Williams Ph.D., Marion Earle Ph.D., Ed Whittle Ph.D., Nathan Ross Ph.D.
Explore the bioscience and chemical manufacturer professional associations that Adesis belongs to.
Here to Help.
Please let us know how we can assist you with your small molecular chemistry needs.